DQS3.F · Akers Biosciences, Inc

-

Please sign in to comment on DQS3.F

1 Comment

Admin

4 years ago

Akers Biosciences, Inc is currently in a long term downtrend where the price is trading 6.6% below its 200 day moving average.

From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.5.

Akers Biosciences, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.

Its net income has dropped by 145.4% to $-3M since the same quarter in the previous year.

Finally, its free cash flow fell by 514.3% to $-3M since the same quarter in the previous year.

Based on the above factors, Akers Biosciences, Inc gets an overall score of 1/5.

Sector	Healthcare
Industry	Medical Instruments & Supplies
Exchange	F
CurrencyCode	EUR
ISIN	None

Beta	0.34
Market Cap	17M
PE Ratio	None
Target Price	None
Dividend Yield	None

ABOUT

Akers Biosciences, Inc

Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.

DQS3.F · Akers Biosciences, Inc

-

Akers Biosciences, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Akers Biosciences, Inc using a moving average strategy